A Study to Evaluate the ePidemiology of anEmia Associated With chroNic Kidney Disease in Patients in Primary Care Using The Stockholm CREAtinine Measurement (SCREAM) Register

Astellas Pharma Europe Ltd.45,637 enrolled

Overview

The objectives of this analysis is to determine the incidence of anemia occurring in patients with chronic kidney disease (CKD) in primary care (i.e. prior to any eventual referral to nephrology care). This analysis also evaluates patient characteristics, anemia treatment and associated cardiovascular risk.

Data will be derived from the Stockholm CREATinine Measurement (SCREAM) cohort, a repository of laboratory data of individuals residing and accessing healthcare in the region of Stockholm and who underwent a creatinine assessment between 2012 - 2018.

Study Type

OBSERVATIONAL

Enrollment

45,637

Conditions

Chronic Kidney Disease

Interventions

Non-interventionalOTHER

Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient entered in SCREAM between 2012 and 2018 * With two consecutive plasma-creatinine test(s) indicating an estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m\^2 * With at least one eligible Hb after eGFR \< 60 mL/min/1.73 m\^2. The date of the first eligible Hb test is the study entry point/index date of the study. Exclusion Criteria: * Patient who has had a recent pregnancy or childbirth (issued diagnosis within 2 years prior to index date). * Patient with ongoing/recent cancer (diagnosed within the previous 3 years), haematological diseases or leukaemia. * Patient with chronic infections (hepatitis, tuberculosis, or human immunodeficiency virus \[HIV\]); note by definition chronic infections are chronic and look back period will be to 1997. * Patients with anemia at baseline (index date), defined by an anemia diagnosis in the year prior, a baseline Hb value within the anemia range according to the WHO definition, or the presence of a recent dispensation of ESA or iron (up to six months prior). * Patient referred to nephrologist within the previous 2 years from cohort entry/ index date.

Locations (1)

SE46001

Stockholm, Sweden

Outcomes

Primary Outcomes

Incidence rate of anemia in adults with non-dialysis dependent CKD stage 3-5 in primary care

Anemia will be defined as the composite of: a diagnosis of anemia, a haemoglobin (Hb) measurement within the defined range for anemia followed by iron (oral or intravenous \[IV\]) or erythropoietin-simulating agent (ESA) treatment within 3 months, a Hb measurement within the defined range for anemia followed by another low Hb measurement \>3 months apart. Anemia as an outcome will be defined by current World Health Organization (WHO) definitions (Hb \< 12 g/dL or 7.45 mmol/L for female and \< 13 g/dL or 8.07 mmol/L for male). The incidence rate of anemia will be calculated as the number of new cases divided by person-time of CKD stage 3-5 patients who were "at risk" of becoming an incident anemia case.

Time frame: 6 years at maximum

Secondary Outcomes

Baseline characteristics associated with anemia occurrence in unreferred CKD stage 3-5 patients

The prevalence of different baseline characteristics of interest will be summarized.

Time frame: On Day 1

Comorbidities associated with anemia occurrence in unreferred CKD stage 3-5 patients

The prevalence of different comorbidities of interest will be summarized.

Time frame: On Day 1

Proportion of patients who initiated anemia treatment after incident of anemia

Anemia treatment initiated within 6 months after development of anemia can include oral iron, IV iron, or erythropoietin-simulating agent (ESA).

Time frame: 6 months

Correlation of incident anemia and the risk of major adverse cardiac events (MACE) events in patients in anemia exposed period

MACE will be defined as all-cause mortality, non-fatal stroke and non-fatal myocardial infarction. Anemia exposed period is from incident anemia until event or end of follow-up.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.